TG Therapeutics reported six-year outcomes for Briumvi (ublituximab) from the ULTIMATE I & II Phase 3 programs at ECTRIMS 2025, alongside dosing-optimization and real-world evidence readouts. Patients maintained on continuous Briumvi saw the annualized relapse rate fall to 0.012 by year six, and nearly 90% remained free of 24-week confirmed disability progression, with safety profiles consistent over time and immunoglobulin levels largely maintained above the lower limit of normal. An ongoing ENHANCE study suggests that consolidating the two loading doses into a single 600 mg day-1 infusion appears well tolerated, with longer infusions associated with fewer infusion reactions in early analyses. ENABLE, the first Phase 4 observational study for Briumvi in routine practice, reported an on-treatment relapse rate of 0.015 with 99.5% of participants relapse-free over 132 patient-years and lower infusion reactions than seen in pivotal trials.
The strategic signal is clear: a third-to-market anti-CD20 is carving out differentiation through durable efficacy aligned with operational simplicity. If label-enabling work confirms a single-day loading dose and supports standardized four-hour infusions, Briumvi’s value proposition shifts from being just another potent B-cell therapy to an efficiency play that reduces chair time, staffing burden, and friction for patients and sites of care. The editorial question is whether this blend of long-term outcomes plus workflow advantages can meaningfully re-order a class dominated by entrenched incumbents.
This matters now because the RMS market is recalibrating around earlier use of highly effective therapies and around healthcare system constraints. For patients, fewer relapses and delayed disability progression remain the ultimate currency, and the emerging signal that earlier, continuous anti-CD20 treatment improves disability outcomes strengthens the case for front-line deployment rather than stepwise escalation. For HCPs and infusion centers, shorter, consolidated infusions could translate to more predictable scheduling, fewer adverse-event interruptions, and better throughput at a time of staffing shortages. For payers, the convergence of clinical durability, lower observed infusion reactions in real-world use, and early improvements in patient-reported outcomes opens the door to a stronger total-cost-of-care narrative focused on relapse avoidance, reduced MRI and steroid use, and less acute care utilization.
Competitive dynamics are intensifying. Ocrelizumab retains scale and guideline familiarity, while ofatumumab offers at-home self-administration that many patients prefer. Briumvi’s counter is precision: glycoengineered CD20 targeting at lower doses, potential single-visit initiation, and increasingly rapid infusions. Stability of immunoglobulins over six years and a lack of new long-term safety signals, if sustained, may ease class-wide concerns that have complicated payer policies and monitoring protocols. The ENABLE data’s demographic breadth also gives Medical Affairs teams material to engage community neurologists and to refine risk communication across diverse populations.
This dataset also reflects broader industry trends: post-approval life-cycle management aimed at operational differentiation; RWE as the credibility bridge between trial efficacy and payer policy; and dosing innovations designed to unlock site-of-care economics. As biosimilar pressures loom for class leaders later this decade, contracting will hinge on more than price. Brands that credibly quantify avoided chair time, minimize infusion reactions, and sustain disability benefits are positioned to shape formulary tiers and step therapies, particularly in integrated delivery networks and capitated models.
The next inflection points are straightforward to watch: results from the randomized, label-enabling dosing trial, any regulatory moves to update the Briumvi label for a single-day loading regimen and standardized infusion times, and the translation of ENABLE outcomes into HEOR packages that resonate with U.S. and EU payers. The strategic question for the sector is whether operational convenience, validated by RWE and embedded in label language, can become a decisive competitive lever in RMS before biosimilar dynamics reset pricing power across the anti-CD20 class.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
